Key facts
- It has raised $14.3M; the latest was Later Stage VC ($14.3M) in Jan 2026.
- Notable investors include Renhe Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for GeneEnlighten
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneEnlighten are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneEnlighten
Developer of advanced cellular-based therapeutic materials intended for clinical and translational research purposes. The company offers biomedical and immunology research capabilities with a comprehensive system covering basic studies, clinical trials, and mid-scale production, featuring large-scale expansion technologies and specialized pipelines for immune cell applications, enabling the healthcare and biotechnology market to access structured development processes, scalable production methods, and validated pathways for innovative treatment approaches.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 46
- Ownership
- Privately Held (backing)
GeneEnlighten doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneEnlighten shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneEnlighten in its N-PORT filings yet. We sweep new filings monthly.